Document Detail

Prospective cohort study of impulse control disorders in Parkinson's disease.
MedLine Citation:
PMID:  23283708     Owner:  NLM     Status:  MEDLINE    
Impulse control disorders (ICDs) are potentially serious side effects of dopamine agonist therapy in Parkinson's disease (PD), but prospective data are lacking about their incidence, time course, and risk factors. This work was a 4-year, prospective cohort study of outpatients with PD and no previous ICDs (N = 164). All subjects treated with a dopamine agonist during the study were followed longitudinally for new-onset ICDs. Baseline characteristics were compared in groups with (ICD+) and without (ICD-) subsequent ICDs. Forty-six subjects were treated with a dopamine agonist, including 25 who were newly treated and 21 who received ongoing dopamine agonist therapy. Of these 46 subjects, 18 (39.1%) developed new-onset ICDs. The timing of ICD onset varied from 3.0 to 114.0 months (median, 23.0) after initiation of dopamine agonist therapy. Baseline demographic characteristics were similar in ICD+ and ICD- groups. At baseline, ICD+ subjects had a greater prevalence of motor complications (61.1% versus 25.0%; P = 0.01) than ICD- subjects, despite comparable total dopaminergic medication usage in both groups (median, 150.0 versus 150.0 levodopa equivalents; P = 0.61). Compared with ICD- subjects, ICD+ subjects had a greater baseline prevalence of caffeine use (100% versus 66.7%; P = 0.007) and higher lifetime prevalence of cigarette smoking (44.4% versus 14.3%; P = 0.04). Peak dopamine agonist doses were higher in ICD+ than ICD- subjects (median 300.0 versus 165.0 L-dopa equivalents; P = 0.03), but cumulative dopamine agonist exposure was similar in both groups. In summary, the timing of new-onset ICDs in PD is highly variable. Risk factors include cigarette smoking, caffeine use, motor complications, and higher peak dopamine agonist dosage.
Jesse Bastiaens; Benjamin J Dorfman; Paul J Christos; Melissa J Nirenberg
Related Documents :
16113428 - Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary...
9387958 - Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients.
24162148 - Bedtime and sleep duration in relation to depressive symptoms among japanese workers.
17240618 - Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination the...
12052098 - Estimating the effect of changes in body mass index on health state preferences.
1742488 - Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multip...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-01-02
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  28     ISSN:  1531-8257     ISO Abbreviation:  Mov. Disord.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-25     Completed Date:  2013-09-20     Revised Date:  2014-02-13    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  327-33     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Movement Disorders Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cohort Studies
Disease-Free Survival
Dopamine Agonists / adverse effects*
Impulse Control Disorders / chemically induced*,  epidemiology*
Longitudinal Studies
Mental Status Schedule
Middle Aged
Parkinson Disease / drug therapy*,  epidemiology
Risk Factors
Grant Support
Reg. No./Substance:
0/Dopamine Agonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Iterative Asymmetric Hydroformylation/Wittig Olefination Sequence.
Next Document:  Commentary: Sir James Mackenzie (1853-1925): An ambiguous pioneer for research in primary care.